Last updated on November 2017

Confirm the efficacy of PRX302 in reducing lower urinary tract symptoms (LUTS) in patients with benign prostatic hyperplasia (BPH).


Brief description of study

Confirm the efficacy of PRX302 in reducing lower urinary tract symptoms (LUTS) in patients with benign prostatic hyperplasia (BPH).

Detailed Study Description

This is a prospective, randomized, double-blind, vehicle-controlled, parallel 2-arm, multi-center, multinational Phase III study of the efficacy and safety of a single intraprostatic injection of PRX302 in reducing LUTS in patients with BPH.

Clinical Study Identifier: TX81649

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Debbie Johnson

First Urology, PSC
Jeffersonville, IN USA
  Connect »